NEU 0.10% $20.71 neuren pharmaceuticals limited

Neuren Media and Analyst Coverage, page-741

  1. 1,556 Posts.
    lightbulb Created with Sketch. 308
    E & P stock focus note came out today- $24.40 valuation. "Our base case valuation of $24.40 is derived from generally conservative or mid-range assumptions and allows for upside from future derisking events"

    The other interesting point is their valuation on NNZ-2591 at $21.5 if successful:
    "We make no changes to our model and we retain our Speculative Buy rating. Our price target remains at A$24.4 per share with a sum
    of the parts risk-adjusted DCF valuation (Figure 4). As a thought exercise, if NNZ-2591 is successful across all four current indications
    under development by NEU, we believe that asset's opportunity to be worth ~A$21.5 per share (see Figure 5)"
    Last edited by TripAces: 17/01/24
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$20.71
Change
-0.020(0.10%)
Mkt cap ! $2.644B
Open High Low Value Volume
$20.90 $21.30 $20.49 $5.295M 255.1K

Buyers (Bids)

No. Vol. Price($)
1 1990 $20.71
 

Sellers (Offers)

Price($) Vol. No.
$20.77 1051 1
View Market Depth
Last trade - 16.10pm 22/05/2024 (20 minute delay) ?
Last
$20.72
  Change
-0.020 ( 0.20 %)
Open High Low Volume
$20.93 $21.30 $20.50 85334
Last updated 15.59pm 22/05/2024 ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.